FDA approves Vyloy for HER2-negative gastric and GEJ cancer
Decision brief
Answer first · skim in under a minute
The FDA approved zolbetuximab-clzb (Vyloy) with chemotherapy for gastric and gastroesophageal junction adenocarcinoma on October 18, 2024. Astellas says it is the first and only CLDN18.2-targeted therapy approved in the U.S. for these cancers.
Zolbetuximab FDA approval on October 18, 2024 brought Vyloy (zolbetuximab-clzb) into U.S. first-line care for CLDN18.2-positive, HER2-negative advanced gastric and gastroesophageal junction adenocarcinoma. Astellas positions the antibody as the first U.S. CLDN18.2-targeted therapy, used with fluoropyrimidine- and platinum-containing chemotherapy.
Contents11 sections
Key Takeaways
- Approval date: October 18, 2024 for Vyloy (zolbetuximab-clzb).
- Population: locally advanced unresectable or metastatic HER2-negative gastric/GEJ adenocarcinoma that is CLDN18.2 positive on an FDA-approved test.
- Regimen: combination with fluoropyrimidine- and platinum-containing chemotherapy in the first-line setting.
- Prior January 2024 Complete Response reflected manufacturing inspection issues; clinical package later supported traditional approval.
What did the zolbetuximab FDA approval cover?
Astellas announced FDA approval of Vyloy for adults whose tumors express claudin 18.2 and who are HER2-negative. The antibody binds CLDN18.2 and depletes positive cells through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
Company disclosure: PR Newswire — Astellas Vyloy FDA approval. Reuters also reported the October 18 action and companion-diagnostic clearance for identifying eligible patients.
How did manufacturing history shape the timeline?
FDA’s multidisciplinary review notes a Complete Response on January 12, 2024 after premarket inspection findings at a manufacturing facility, even though reviewers considered the clinical evidence adequate for traditional approval. Astellas resubmitted on May 9, 2024 responding to those quality deficiencies, clearing the path to the October approval.
See the agency review summary on accessdata.fda.gov (BLA 761365).
Clinical and diagnostic requirements
Patients need CLDN18.2 positivity confirmed with an FDA-approved companion diagnostic before starting Vyloy. The labeled setting is first-line unresectable or metastatic disease in HER2-negative gastric or GEJ adenocarcinoma. That biomarker gate will determine real-world addressable population size more than headline incidence of gastric cancer alone.
- Target: CLDN18.2 transmembrane protein
- Partner chemo: fluoropyrimidine + platinum backbone
- Line of therapy: first-line advanced/metastatic
Competitive implications
First-in-class U.S. approval for a CLDN18.2 cytolytic antibody creates a new biomarker-defined niche alongside HER2-directed and PD-1–based strategies. Competitors pursuing CLDN18.2 ADCs or other modalities will need differentiation on efficacy, toxicity—especially gastrointestinal events historically linked to CLDN18.2 agents—and diagnostic logistics.
What remains unproven
Approval does not establish superiority versus every alternative first-line regimen in a single head-to-head U.S. study. Long-term survival beyond the registrational follow-up, sequencing after progression, and real-world diagnostic turnaround times remain open questions. List-price anecdotes in secondary coverage should be verified against company contracts before modeling net cost.
SPOTLIGHT and GLOW as the clinical backbone
Registrational confidence for zolbetuximab rests on late-stage trials that tested the antibody with chemotherapy backbones in CLDN18.2-positive, HER2-negative disease. Astellas’ approval communications describe first-line use for locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma when CLDN18.2 positivity is confirmed. Oncologists will need pathology workflows that can return CLDN18.2 status with the same reliability expected for HER2 testing.
Because Vyloy is given with fluoropyrimidine- and platinum-containing chemotherapy, supportive-care planning should anticipate overlapping toxicities from both the antibody and the cytotoxic partners. Gastrointestinal adverse events historically associated with CLDN18.2 targeting deserve proactive monitoring in the first treatment cycles.
Market access after first-in-class entry
First-in-class U.S. status may help formulary discussions, but payers will still demand biomarker confirmation and may stage coverage behind documentation of HER2-negative and CLDN18.2-positive status. Companion-diagnostic turnaround time becomes a commercial bottleneck: every day of diagnostic delay is a day of delayed first-line starts. Competitive CLDN18.2 programs in development will watch real-world uptake of Vyloy as a proxy for how quickly the biomarker can be operationalized outside academic centers.
Related NovaPharma coverage
- Datopotamab deruxtecan FDA vs EMA path
- J&J TREMFYA ulcerative colitis data
- AbbVie Cerevel acquisition close
Frequently Asked Questions
What is the Vyloy indication after zolbetuximab FDA approval?
Vyloy (zolbetuximab-clzb) is approved with fluoropyrimidine- and platinum-containing chemotherapy for first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma whose tumors are CLDN18.2 positive by an FDA-approved test.
When did the FDA approve Vyloy?
The FDA approved Vyloy on October 18, 2024. Astellas described it as the first and only CLDN18.2-targeted therapy approved in the United States.
What delayed the earlier application?
FDA issued a Complete Response in January 2024 related to manufacturing-facility inspection deficiencies, not clinical-efficacy concerns; Astellas resubmitted in May 2024 before the October approval.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Vyloy.
Unlock full calendar →Astellas Pharma pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
